Inhibition of PD-1, PD-L1 and CTLA-4 activates not only tumor-specific T cells but also autoimmunity, and tumor-specific neoplastic antigens and normal tissue antigens may be cross-reactive. The gene discussed is CTLA4; the disease is neoplasm.